KORU Medical Systems, Inc.
Close on Oct 19, 2026
- Market cap
- $149.52M
- P/E (TTM)
- –
- Dividend yield
- –
About KORU Medical Systems
Surgical & Medical Instruments & Apparatus, SIC 3841
KORU Medical Systems develops, manufactures, and commercializes mechanical infusion devices designed for subcutaneous drug delivery. Its core product line, the FREEDOM Infusion System, features the FREEDOM60 and FreedomEdge syringe drivers, subcutaneous safety needle sets, and precision flow rate tubing. These systems administer subcutaneous medications such as immunoglobulin for primary immunodeficiency and chronic inflammatory demyelinating polyneuropathy, alongside treatments for conditions like generalized myasthenia gravis. The business operates across three primary streams: domestic core, international core, and biopharmaceutical services, which offers testing and engineering support for clinical trials. The company provides its products and services to pharmaceutical firms, home infusion providers, specialty pharmacies, and distributors.
The company distributes its devices through three domestic distributors in the United States and six distributors internationally. It manufactures all infusion pumps and some consumables at its facility in Mahwah, New Jersey, while an external contract partner in Nicaragua produces additional consumables and maintains warehousing in Miami, Florida. KORU Medical Systems is headquartered in Mahwah, New Jersey.
Summary of the business section of KORU Medical Systems's latest annual report, written by StockData.
Company profile
Company
- Legal name
- KORU Medical Systems, Inc.
- Founded
- 1980
- Headquarters
- Mahwah, NJ
- Address
- 100 Corporate Drive 07430
- Phone
- (845) 469-2042
- Employees
- 73, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Cherry Bekaert LLP, Tampa, Florida
Stock & identifiers
- Ticker
- KRMD
- Exchange
- Nasdaq
- Shares outstanding
- 46M, Aug 5, 2026
- Public float
- $119.08M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 704440
- CUSIP
- 759910102
- ISIN
- US7599101026
- EIN
- 13-3044880
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Linda M. Tharby | Chief Executive Officer, Director | 620,622 |
| Adam R. Kalbermatten | Chief Commercial Officer | 394,017 |
| Eric Schiller | Chief Technology Officer | 5,000 |
| Christopher Pazdan | Chief Operating Officer | 308,988 |
| Thomas Edward Adams | Chief Financial Officer | 307,688 |
| Kenneth E. Miller | Chief Commercial Officer | 5,893 |
| Shahriar Matin | Director | 101,144 |
| Donna French | Director | 98,514 |
| R. John Fletcher | Director | 232,157 |
| Robert Cascella | Director | 98,155 |
| Joseph M. Manko Jr. | Director | 506,033 |
| Edward Wholihan | Director | 51,312 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Linda Tharby | $1.74M | $3.25M | $1.77M | $163 | – |
| FY2024 Linda Tharby | $1.27M | $1.93M | $598.87K | $108 | – |
| FY2023 Linda Tharby | $713.37K | -$1.19M | $547.30K | $69 | – |
| FY2022 Linda Tharby | $962.60K | $1.45M | $841.72K | $119 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 73 full time employees, including 4 international”
Corporate history
Events identified from SEC filings